- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma
Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
In this edition of Managed Care Cast, Executive Editor Mary Caffrey speaks with Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute. Gordan discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Review the NCCN guideline update discussed in this podcast.
The guidelines follow the Second revision of the International Staging System (R2-ISS), which appeared in the December 2022 issue of the Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.1
Listen above or on one of these podcast services:
Reference
- D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the Harmony project. J Clin Oncol 2022;40(29):3406-3418. doi:10.1200/JCO.21.02614
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
ICYMI: Highlights From IMS 2024
December 17th 2024The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
Read More
